## NKFIH K 109783

## Final report

Major aim of the project was to investigate the effect of $\alpha_{2}$-plasmin inhibitor ( $\alpha_{2}$-PI) plasma level, the ratio of N -terminal $\alpha_{2}$-PI variants in the plasma and the $\alpha_{2}$-PI Arg6Trp polymorphism on the risk of myocardial infarction. The amount of $\alpha_{2}$-PI attached to circulating fibrinogen was also examined.

Development of sandwich type immunoassay for the measurement of N-terminally intact $\alpha_{2}$-PI (Met1- $\alpha_{2}$-PI) using newly generated monoclonal and commercially available polyclonal antibodies.
We started the work with generation of monoclonal antibodies against the peptide corresponding to the N -terminal twelve amino acids of Met1- $\alpha_{2}$-PI (Fig 1., P1-12). We fused $\mathrm{Sp}-2$ myeloma cells and spleen cells of mice immunized with the peptideKLH conjugate. Antibody production was tested by indirect ELISA systems, in which peptide conjugated to bovine serum albumin, un-conjugated peptide or native $\alpha_{2}$-PI were coated onto the surface of the ELISA plate. Seven antibody-producing hybrid cell lines were selected and cloned which produced antibody that bound equally well to the peptide and the native $\alpha_{2}$-PI protein isolated from human plasma. Antibodies were purified from ascites fluid by Protein G affinity chromatography and tested in sandwich type ELISA assay as capture antibody, while HRPO labelled polyclonal anti- $\alpha_{2}$-PI was used as tag antibody. The monoclonal antibody $3 / 2 \mathrm{D} 6 \mathrm{~F} 4$ was selected for developing a sandwich type ELISA to measure Met1- $\alpha_{2}$-PI in human plasma. Unfortunately the assay measured much lower level of Met1- $\alpha_{2}$-PI in normal plasma samples than expected and it turned out, that the p.Arg6Trp polymorphism of $\alpha_{2}$-PI influenced the antigen-antibody reaction. None of the selected antibodies reacted with $\alpha_{2}-\mathrm{PI}(\operatorname{Trp} 6)$. In order to overcome the problem caused by the effect of R6W polymorphism we chose an alternative way to produce antibodies that bind specifically to the N -terminally intact $\alpha_{2}$-PI, irrespective of the polymorphism. We synthesized a new peptide that does not contain the polymorphic site, but contains the APCE cleaving site (Fig 1., P8-20).


Fig 1. Peptides corresponding to the N -terminal end of $\alpha_{2}$-PI

The peptide was conjugated to KLH for immunization and BSA for testing of antibody production of hybrid cells. Mice were successfully immunised with the new peptide-KLH conjugate and the protocol of monoclonal antibody production was repeated several time. We were able to select an antibody that can bind only the Leu8Leu20 peptide and intact recombinant Met1- $\alpha_{2}$-PI protein and does not react with the P1-12 or P13-24 peptides, which means that the epitope of the antibody is lost when APCE cleaves off the N -terminal twelve amino acids from Met $1 \alpha_{2}$-PI. The antibody
was purified by Protein G affinity chromatography and conjugated to horseradish peroxidase enzyme. We wanted to develop a sandwich type immunoassay using this antibody and a second antibody that can bind all $\alpha_{2}-\mathrm{PI}$ isoforms equally well. However, the sandwich system did not work with plasma samples. We repeated the antibody generating protocol several times in order to find a suitable antibody, but did not succeed. Therefore, we changed our strategy again; we immunized mice with purified native $\alpha_{2}$-PI protein and the specificity of the generated antibodies were tested by investigating their binding to native $\alpha_{2}-\mathrm{PI}$ and to different peptides corresponding to the N -terminal end of $\alpha_{2}$-PI (Fig 1.). This approach is generally thought to be less effective to get antibody to a specific part of the antigen, but in our case it seems to be more successful. We identified several positive hybrid cultures with different epitope specificities (Table 1.)

Table 1. Reaction of newly generated antibodies with purified $\alpha_{2}$-PI and its N terminal peptides

| Hybridoma <br> code | OD value in different indirect ELISAs |  |  |
| :--- | :--- | :--- | :--- |
|  | $\boldsymbol{\alpha}_{\mathbf{2}} \mathbf{- P I}$ | $\mathbf{P 1 - 1 2}$ | $\mathbf{P 8}-20$ |
| 1A1 | 3.27 | 0 | 0 |
| 1B1 | 1.03 | 0 | 0 |
| 1B4 | 1.34 | 1.36 | 0.24 |
| 1C2 | 0.79 | 0 | 0 |
| 1C3 | 1.21 | 0.10 | 0 |
| 1D2 | 1.10 | 0 | 0 |
| 1F1 | 2.16 | 0.44 | 0 |
| 1F4 | 1.20 | 0 | 0.73 |
| 2A3 | 1.52 | 0 | 0 |
| 2B3 | 3.51 | 0 | 0 |
| 2E3 | 1.57 | 0 | 0 |

The reaction pattern of antibodies 1B4 and 1F4 is promising. After cloning the hybrid lines the epitope specificity of antibodies will be tested again and their reaction (as capture antibody) with plasma $\alpha_{2}$-PI in sandwich type ELISA will also be investigated. Antibodies reacting with other parts of the $\alpha_{2}$-PI molecule will also be tested as tag antibody in the sandwich ELISA system. The continuation of the work is planned within the framework of the ongoing project of principal investigator "The role of alpha2-plasmin inhibitor natural heterogeneity in thrombotic diseases" (NKFI K120633).

Determination of the ratio of N -terminal $\alpha_{2}$-PI variants in normal plasma samples, and its correlation with the $\alpha_{2}$-PI R6W genotype.
$\alpha_{2}$-PI p.Arg6Trp genotype was determined in DNA samples of 265 apparently healthy volunteers (age: 18-70 years). The frequency of Arg6 and Trp6 alleles was 0.779 and 0.221 , respectively. Our results well agreed with the results published earlier (Arg6: 0.795, Trp6: 0.205; Christiansen et al. Blood, 2007;109:5286-92.).

Total $\alpha_{2}$-PI antigen and activity levels were measured from 221 samples using the ELISA method developed in our laboratory and Berichrom $\alpha_{2}$-Antiplasmin kit,
respectively. Fibrinogen, FXIII activity, FXIII- $\mathrm{A}_{2} \mathrm{~B}_{2}$ and FXIII-B antigen levels were also determined.
Results: $\alpha_{2}$-PI antigen and activity results did not show Gaussian distribution, the median (min, max) plasma concentration and activity were $63.2(34,87,5) \mathrm{mg} / \mathrm{L}$ and $120(46,150) \%$ respectively. There were no gender differences in the antigen and activity levels and age also was without effect. Total $\alpha_{2}$-PI antigen showed significant correlation with the activity levels ( $\mathrm{r}=0.591, \mathrm{p}<0,001$ ) and moderate, but statistically significant correlation with fibrinogen ( $\mathrm{r}=0,291, \mathrm{p}<0,001$ ) and FXIII-B antigen ( $\mathrm{r}=0,241, \mathrm{p}<0,001$ ). $\alpha_{2}$-PI p.Arg6Trp genotype had no significant effect on total $\alpha_{2}$-PI antigen and activity levels.
Plasma aliquots are stored for the determination of Metl $\alpha_{2}$-PI isoform using the method that is under development.
$\alpha_{2}$-PI R6W genotype frequency in the general Hungarian population.
$\alpha_{2}$-PI R6W genotype was determined in DNA samples of 999 individuals representing the general Hungarian population. Individuals were recruited in the framework of the Hungarian General Practitioners’ Morbidity Sentinel Stations Program. The frequency of R and W alleles was 0.785 and 0.215 , respectively.
$\alpha_{2}$-PI Arg6 allele frequencies in the general population and in the healthy control group did not differ significantly.

Effect of $\alpha_{2}$-PI R6W genotype on the risk of myocardial infarction.
$\alpha_{2}$-PI R6W genotype was determined in stored DNA samples of the CAD study group investigated earlier in our laboratory. The study group included 750 consecutive patients admitted for coronary angiography to investigate suspected coronary artery disease. Patients were recruited for the study from a single centre (Institute of Cardiology, University of Debrecen, Debrecen, Hungary) over a one and a half year period. Patients with $\geq 50 \%$ stenosis in a major coronary artery or in one of their branches were graded as coronary sclerosis positive (CS+), while patients with no or less significant stenosis were graded as CS-. Patients with positive or negative history of MI were classified as MI+ or MI-, respectively. Patients without significant coronary stenosis and with the lack of history of MI were considered as the clinical control group (CS-MI-) to which subgroups of patients with CS and/or MI (CS-MI+, CS+MI-, CS+MI+) were compared. Table 2 shows the $\alpha_{2}$-PI R6W genotype distribution in the different patient groups.

Table 2. $\alpha_{2}$-PI R6W genotype distributions in the population control and CAD patient groups. Results are presented as N (\%)

| Allele | Population <br> control | Clinical <br> control | CS-MI+ | CS+MI- | CS+MI+ |
| :--- | :--- | :--- | :--- | :--- | :--- |
| CC | $625(62.6)$ | $171(66.0)$ | $18(64.3)$ | $146(62.4)$ | $151(65.9)$ |
| CT | $318(31.8)$ | $75(28.9)$ | $7(25.0)$ | $76(32.5)$ | $70(30.6)$ |
| TT | $56(5.6)$ | $13(5.0)$ | $3(10.7)$ | $12(5.1)$ | $8(3.5)$ |
| Total <br> number | 999 | 259 | 28 | 234 | 229 |

Main results of the study:

- $\alpha 2$-PI Arg6Trp genotype distribution did not differ significantly among the different control and patient groups (Table 1.)
- The presence of Trp allele did not influence the risk of CAS or MI when patient groups were compared to the clinical control or population control groups. Homozygous Trp6 genotype conferred a decreased, but statistically not significant risk of MI (Table 3.)

Table 3. Effect of $\alpha 2$-PI Arg6Trp polymorphism on the risk of CAS or MI (OR ( $95 \%$ CI); p)

| Control group | Genotype | CAS+MI- | CAS+MI+ |
| :---: | :---: | :---: | :---: |
| Population <br> control | OR for Trp6 <br> carriers | $1,007(0,751-1,351) ;$ <br> 0,962 | $0,863(0,638-1,167) ;$ <br> 0,340 |
| Population <br> control | OR for Trp6 <br> homozygotes | $0,917(0,479-1,755) ;$ <br> 0,794 | $0,591(0,276-1,267) ;$ <br> 0,176 |
| Clinical control | OR for Trp6 <br> carriers* | $1,109(0,740-1,661) ;$ <br> 0,616 | $0,972(0,635-1,487) ;$ <br> 0,896 |
| Clinical control | OR for Trp6 <br> homozygotes* | $0,908(0,368-2,239) ;$ <br> 0,834 | $0,539(0,192-1,513) ;$ <br> 0,240 |

The results were presented at the XXV Congress of the International Society on Thrombosis and Haemostasis, Toronto, Canada, 20-25. June 2015.

Effect of $\alpha_{2}$-PI R6W genotype on the risk of myocardial infarction in young patients 116 patients who had coronary sclerosis proven by coronary angiography and had ST elevation myocardial infarction (MI) below the age of 40 and 120 healthy controls (HC) were enrolled in this part of the study. Serum cholesterol, LDL-cholesterol, HDL-cholesterol, triglyceride, apoAI, apoB, lipoprotein (a), homocysteine, folic acid, vitamin B12, CRP, and plasma fibrinogen, total $\alpha 2$-PI antigen, $\alpha 2$-PI activity, FXIII $\mathrm{A}_{2} \mathrm{~B}_{2}$ and FXIII-B antigen, FXIII activity were measured, and $\alpha 2$-PI Arg6Trp, FXIIIA Val34Leu, FXIII-B His95Arg and FXIII-B Intron K genotypes were determined. The main results:

Table 4. Main characteristics of the patients groups

|  | HC <br> $(\mathbf{n = 1 2 0})$ | MI <br> $(\mathbf{n = 1 1 6 )}$ | p |
| :--- | :--- | :--- | :--- |
| Age (median (min - max) | $31.5(24-40)$ | $36(14-40)$ | $<0.001$ |
| Male/female (n) | $58 / 62$ | $91 / 25$ | $<0.001$ |
| Diabetes mellitus (\%) | 0 | 14 | $<0.001$ |
| Smoking (never/current/ex) <br> (\%) | $60 / 28 / 12$ | $19 / 54 / 27$ | $<0.001$ |
| Positive family history (\%) | 38 | 72 | $<0.001$ |
| Hypertension (\%) | 11 | 43 | $<0.001$ |
| Hyperlipidemia (\%) | ND | 87 | NA |
| BMI (mean $\pm$ SD) | $24.5 \pm 4.2$ | $28.4 \pm 5.4$ | $<0.001$ |
| Fibrinogen g/L (mean $\pm$ SD) | $3.19 \pm 0.60$ | $3.65 \pm 0.77$ | $<0.001$ |
| $\alpha 2$-PI Arg6Trp $\quad \mathrm{n}(\%)$ |  |  |  |
| RR | $77(64.2)$ | $72(62.1)$ |  |


| RW | $39(32.5)$ | $36(31.0)$ |  |
| :--- | :--- | :--- | :--- |
| WW | $4(3.3)$ | $8(6.9)$ |  |
| W carrier frequency (\%) | 35.8 | 37.9 | 0.788 |
| MAF (\%) | 0.20 | 0.22 |  |

Positive family history was defined as MI, stroke, or non-traumatic lower limb amputation in first-degree relatives; Hypertension: systolic blood pressure $\geq 140$ mmHg and/or diastolic pressure $\geq 90 \mathrm{mmHg}$ or the patient was on anti-hypertension medication prior admission; Hyperlipidemia: LDL-cholesterol level $>3.4 \mathrm{mmol} / \mathrm{l}$ or the patient was on cholesterol lowering medication prior admission; ND: not determined; NA: non applicable

- Trp allele frequency did not differ significantly among the study groups and were in good agreement with data obtained in the CAD study group and from the HapMap database.
- The presence of the Trp allele did not influence the risk for MI; OR ( $95 \% \mathrm{CI} ; \mathrm{p}$ ) was 1.104 (0.595-2.046; 0.755).
- $\alpha 2$-PI antigen levels adjusted to gender and fibrinogen (mean $(95 \% \mathrm{CI})$ ) were significantly elevated in MI patients compared to controls (MI: $74.32 \mathrm{mg} / \mathrm{L}$ (73.677.1), HC, $64.0 \mathrm{mg} / \mathrm{L}(62.5-65.5)$.
- $\alpha 2$-PI levels in the upper tertile (above $73.3 \mathrm{mg} / \mathrm{L}$ ) increased the risk of MI (OR MI vs HC, 7.25, 95\%CI, 3.53-14,87).
Results were presented at the $61^{\text {st }}$ Annual Meeting of the Society of Thrombosis and Haemostasis Research, Basel, Switzerland, 15-18 February 2017. and at the XXVI ISTH Congress and $63{ }^{\text {rd }}$ Annual SSC Meeting, Berlin, Germany, July 8-13 2017. An MSc student participated in the measurement of total $\alpha 2$-PI antigen and activity levels, therefore part of the results were presented in a diploma-thesis. The manuscript is under preparation.

Effect of factor XIII levels and polymorphisms on the risk of myocardial infarction in young patients
In the young patient cohort we also investigated the association of FXIII levels with the risk of myocardial infarction. FXIII activity and FXIII- $\mathrm{A}_{2} \mathrm{~B}_{2}$ antigen levels were significantly elevated in MI. Smoking had an independent increasing effect on FXIII activity and FXIII- $\mathrm{A}_{2} \mathrm{~B}_{2}$ antigen. The effect of smoking on coronary thrombus formation may partially be attributed to its FXIII increasing effect (Balogh L, Katona É, Mezei ZA et al. Effect of factor XIII levels and polymorphisms on the risk of myocardial infarction in young patients. Molecular and Cellular Biochemistry 2018;448:199-209.).

The amount of covalently cross-linked $\alpha 2-\mathrm{PI}$ in circulating fibrinogen.
To investigate the amount of $\alpha_{2}$-PI covalently attached to circulating fibrinogen monoclonal anti- $\alpha_{2}$-PI antibody that binds all plasmatic form of $\alpha_{2}$-PI (developed in our laboratory) was coupled covalently to Sepharose 4B gel and used for the immunprecipitation of $\alpha_{2}$-PI from citrated normal human plasma samples. After washing of the gel, the precipitated $\alpha_{2}$-PI and other molecules that bound to it were analysed by two different techniques.
1/ Immuno-precipitated proteins were eluted by SDS-PAGE sample buffer that was followed by the addition of 2-mercaptoethanol to reduce the proteins. Reduced
proteins were separated by SDS-PAGE (two parallel gels), electro-blotted to PVDF membranes and analysed by Western blotting technique using polyclonal anti- $\alpha_{2}-\mathrm{PI}$ or polyclonal anti-fibrinogen antibodies and ECL detection system. By this technique we detected only isolated fibrinogen subunits or $\alpha_{2}$-PI with 67 kD molecular weight and high molecular weight cross-linked complexes were not seen either of the Western blot membrane. From these results it seems that in contrary to the published results $\alpha_{2}$-PI in the circulation doesn't binds covalently to fibrinogen. Western blots were analysed by quantitative densitometry and $0.07-0.8 \mathrm{nM}$ fibrinogen $/ 1 \mathrm{nM} \alpha_{2}$-PI was detected in the precipitates. The reproducibility of the method however was not acceptable.
2/ To determine the amount of non-covalently attached $\alpha_{2}$-PI-fibrinogen complex in the plasma accurately we developed an in-house fibrinogen ELISA assay and modified the immuno-precipitation protocol. Precipitation was performed in compact reaction columns developed for small-scale affinity purification, which provides effective washing of the gel. Proteins bound to monoclonal anti- $\alpha_{2}$-PI-Sepharose 4B gel were eluted by glycine buffer ( $\mathrm{pH}: 2.7$ ) and after neutralizing the pH fibrinogen and $\alpha_{2}$-PI were measured by ELISA methods developed in our laboratory. In the precipitate of 20 healthy volunteers $11.8 \pm 1.1 \mu \mathrm{~g} / \mathrm{ml}(176 \pm 17 \mathrm{nM}) \alpha_{2}-\mathrm{PI}$ and $353 \pm 408$ $\mathrm{ng} / \mathrm{ml}(1.04 \pm 1.2 \mathrm{nM})$ fibrinogen was detected, which means that $\alpha_{2}$-PI in the circulation is either not bound to fibrinogen or the affinity is very low.
The effect of fibrin monomer formation on the binding of $\alpha_{2}$-PI was also investigated by this technique. We added $\mathrm{Ca}^{2+}$ and thrombin to normal human plasma samples in order to cleave off the fibrinopeptide A and B while GPRP peptide and IAA were present to inhibit fibrin polymerization and FXIII activity, respectively. The amount of fibrin(ogen) in the eluate was increased by $\approx 10$ times after fibrin monomer formation.
The results were verified using appropriate negative controls. Using normal mouse IgG covalently attached to Sepharose 4B for the immuno-precipitation of plasma samples and applying different surface blocking techniques we confirmed that fibrinogen measured in the eluates of anti- $\alpha_{2}$-PI-Sepharose 4B gel were precipitated together with $\alpha_{2}-\mathrm{PI}$ and was not bound to the gel by nonspecific binding.
Part of the results was presented at the congress of Hungarian Society on Thrombosis and Haemostasis (2014). The manuscript is under preparation.

